Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 05, 2026 08:00 ET | Source: Kestrel Therapeutics Inc.

Kestrel Therapeutics Announces IND Clearance by U.S. FDA of KST-6051, a Potential Best-in-Class Pan-KRAS Inhibitor, Enabling Initiation of Phase 1 Trial

WATERTOWN, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Kestrel Therapeutics Inc. (“Kestrel” or the “Company”), a clinical stage biotechnology company developing next-generation small-molecule...